Cristina Vazquez‐Mateo

Attainment of treat-to-target endpoints in SLE patients with high disease activity in the atacicept phase 2b ADDRESS II study

Eric F. Morand, David Isenberg, Daniel J. Wallace et al. · Lara D. Veeken · 2020 · 50 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

STRATUS: A Phase II Study of Abituzumab in Patients With Systemic Sclerosis–associated Interstitial Lung Disease

Dinesh Khanna, Donald P. Tashkin, Athol U. Wells et al. · The Journal of Rheumatology · 2020 · 28 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +13

Safety and clinical activity of atacicept in the long-term extension of the phase 2b ADDRESS II study in systemic lupus erythematosus

Daniel J. Wallace, David Isenberg, Eric F. Morand et al. · Lara D. Veeken · 2021 · 28 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +14

Distinct p21 requirements for regulating normal and self-reactive T cells through IFN-γ production

Lidia Daszkiewicz, Cristina Vazquez‐Mateo, Gorjana Rackov et al. · Scientific Reports · 2015 · 27 citations · Full text

Life Sciences, Immunology, Pathology +17

Applying Modeling and Simulations for Rational Dose Selection of Novel Toll‐Like Receptor 7/8 Inhibitor Enpatoran for Indications of High Medical Need

Lena Klopp‐Schulze, Jamie Shaw, Jennifer Dong et al. · Clinical Pharmacology & Therapeutics · 2022 · 18 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17